The Pan-Provincial Vaccine Enterprise Inc. (PREVENT) is a Centre of Excellence for Commercialization and Research (CERC) established in February, 2008 through the Networks of Centres of Excellence program. PREVENT is a not-for-profit corporation headquartered at the Vaccine and Infectious Disease Organization, University of Saskatchewan.
- Prior to PREVENT, Canada lacked a national mechanism to prioritize the development of nascent vaccine candidates in terms of public health demands, and independent from multi-national pharmaceutical priorities. PREVENT has a mandate to fast-track veterinary and human vaccine development for diseases of major public health concern, and to address the commercialization challenges faced by Canada’s biotechnology industry.
- As a unique pan-Canadian vaccine commercialization platform, PREVENT accelerates the most promising Canadian vaccine discoveries through preclinical and early clinical evaluation, catalyzing the commercially viable development of products that address significant public health needs. This reduces the risk shouldered by industry through the facilitation of time and labour intensive critical mid-stage vaccine development. PREVENT further supports this development as vaccine candidates are passed into the hands of receptor organizations, either in the private or public sector.
- PREVENT mobilizes and pools the resources of a multi-disciplinary body of expertise which is comprised of experts from public health, academic organizations, research institutes, the vaccine industry, and the investment community. The founding partners of this collaborative effort include the Vaccine and Infectious Disease Organization and International Vaccine Centre (VIDO-InterVac) in Saskatoon, the Canadian Center for Vaccinology (CCfV) in Halifax, and the BC Centre for Disease Control (BCCDC) in Vancouver.
PREVENT’s Business Model for Vaccine Development
PREVENT will strengthen Canada’s vaccine industry by leveraging current investments in R&D and nurturing partnerships between the public and private sector leading to an improved global competitiveness. Moreover, by keeping manufacturing and clinical trials within Canada, PREVENT will accelerate the rate at which essential vaccines reach the Canadian marketplace, resulting in improved access to vaccines that lead to significant health and economic benefits.